ImmunityBio (IBRX) Cash from Financing Activities (2014 - 2026)

ImmunityBio (IBRX) has reported Cash from Financing Activities for 13 consecutive years, with $223.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 22903.05% year-over-year to $223.9 million; the TTM figure through Mar 2026 stood at $625.1 million (up 131.17% YoY), while the FY2025 annual figure was $400.2 million, up 42.12% from the prior year.
• Cash from Financing Activities improved to $223.9 million in Q1 2026 per IBRX's latest filing, from $54.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $237.5 million in Q3 2023 and bottomed at -$982000.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $99.9 million across 5 years, with a median of $106.9 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 289513.33% — and 2025, when it slumped 109.6%.
• ImmunityBio's Cash from Financing Activities stood at $109.9 million in 2022, then surged by 82.41% to $200.5 million in 2023, then slumped by 46.68% to $106.9 million in 2024, then sank by 48.66% to $54.9 million in 2025, then jumped by 307.92% to $223.9 million in 2026.
• Business Quant data shows IBRX's Cash from Financing Activities at $223.9 million in Q1 2026, $54.9 million in Q4 2025, and $173.5 million in Q3 2025.